Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share arrangement. Rani has exclusive rights to lead development and commercialization of RT-114 in the United States, Europe, Canada and Australia, and ProGen has exclusive rights to lead development and commercialization in the rest of the world. Each party has certain rights to sublicense in its territories. Rani is designated to lead operationally in conducting preclinical and development activities through the Phase 1 program, which is expected to initiate in 2025. As part of this agreement, there is no upfront payment or financial exchange between the companies.
根據合作協議的條款，Rani和ProGen同意在全球範圍內共同負責 RT-114 的開發和商業化，包括50/50的成本和收入分成安排。Rani 擁有在美國、歐洲、加拿大和澳大利亞領導 RT-114 開發和商業化的專有權，ProGen 擁有領導世界其他地區開發和商業化的專有權。各方都有在其領土上進行再許可的某些權利。Rani被指定領導通過第一階段計劃開展臨床前和開發活動的運營，該計劃預計於2025年啓動。作爲本協議的一部分，兩家公司之間沒有預付款或財務交換。
譯文內容由第三人軟體翻譯。